Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2011

Open Access 01-12-2011 | Review

Stem cells in clinical practice: applications and warnings

Authors: Daniele Lodi, Tommaso Iannitti, Beniamino Palmieri

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2011

Login to get access

Abstract

Stem cells are a relevant source of information about cellular differentiation, molecular processes and tissue homeostasis, but also one of the most putative biological tools to treat degenerative diseases. This review focuses on human stem cells clinical and experimental applications. Our aim is to take a correct view of the available stem cell subtypes and their rational use in the medical area, with a specific focus on their therapeutic benefits and side effects. We have reviewed the main clinical trials dividing them basing on their clinical applications, and taking into account the ethical issue associated with the stem cell therapy.

Methods

We have searched Pubmed/Medline for clinical trials, involving the use of human stem cells, using the key words "stem cells" combined with the key words "transplantation", "pathology", "guidelines", "properties" and "risks". All the relevant clinical trials have been included. The results have been divided into different categories, basing on the way stem cells have been employed in different pathological conditions.
Literature
1.
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science. 1999, 284 (5411): 143-147. 10.1126/science.284.5411.143.PubMedCrossRef
2.
Mayhall EA, Paffett-Lugassy N, Zon LI: The clinical potential of stem cells. Curr Opin Cell Biol. 2004, 16 (6): 713-720. 10.1016/j.ceb.2004.09.007.PubMedCrossRef
3.
Fortier LA: Stem cells: classifications, controversies, and clinical applications. Vet Surg. 2005, 34 (5): 415-423. 10.1111/j.1532-950X.2005.00063.x.PubMedCrossRef
4.
5.
Doe CQ: Neural stem cells: balancing self-renewal with differentiation. Development. 2008, 135 (9): 1575-1587. 10.1242/dev.014977.PubMedCrossRef
6.
Knoblich JA: Mechanisms of asymmetric stem cell division. Cell. 2008, 132 (4): 583-597. 10.1016/j.cell.2008.02.007.PubMedCrossRef
7.
Zhong W, Chia W: Neurogenesis and asymmetric cell division. Curr Opin Neurobiol. 2008, 18 (1): 4-11. 10.1016/j.conb.2008.05.002.PubMedCrossRef
8.
Baksh D, Song L, Tuan RS: Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med. 2004, 8 (3): 301-316. 10.1111/j.1582-4934.2004.tb00320.x.PubMedCrossRef
9.
Barry FP, Murphy JM: Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol. 2004, 36 (4): 568-584. 10.1016/j.biocel.2003.11.001.PubMedCrossRef
10.
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM: Embryonic stem cell lines derived from human blastocysts. Science. 1998, 282 (5391): 1145-1147. 10.1126/science.282.5391.1145.PubMedCrossRef
11.
Baharvand H, Ashtiani SK, Valojerdi MR, Shahverdi A, Taee A, Sabour D: Establishment and in vitro differentiation of a new embryonic stem cell line from human blastocyst. Differentiation. 2004, 72 (5): 224-229. 10.1111/j.1432-0436.2004.07205005.x.PubMedCrossRef
12.
Ladurner P, Rieger R, Baguna J: Spatial distribution and differentiation potential of stem cells in hatchlings and adults in the marine platyhelminth macrostomum sp.: a bromodeoxyuridine analysis. Dev Biol. 2000, 226 (2): 231-241. 10.1006/dbio.2000.9867.PubMedCrossRef
13.
Fang TC, Alison MR, Wright NA, Poulsom R: Adult stem cell plasticity: will engineered tissues be rejected?. Int J Exp Pathol. 2004, 85 (3): 115-124. 10.1111/j.0959-9673.2004.00380.x.PubMedCentralPubMedCrossRef
14.
Pera MF, Reubinoff B, Trounson A: Human embryonic stem cells. J Cell Sci. 2000, 113 (Pt 1): 5-10.PubMed
15.
Pessina A, Gribaldo L: The key role of adult stem cells: therapeutic perspectives. Curr Med Res Opin. 2006, 22 (11): 2287-2300. 10.1185/030079906X148517.PubMedCrossRef
16.
Gucciardo L, Lories R, Ochsenbein-Kolble N, Done E, Zwijsen A, Deprest J: Fetal mesenchymal stem cells: isolation, properties and potential use in perinatology and regenerative medicine. BJOG. 2009, 116 (2): 166-172. 10.1111/j.1471-0528.2008.02005.x.PubMedCrossRef
17.
Blau HM, Brazelton TR, Weimann JM: The evolving concept of a stem cell: entity or function?. Cell. 2001, 105 (7): 829-841. 10.1016/S0092-8674(01)00409-3.PubMedCrossRef
18.
Joshi D, Behari M: Neuronal stem cells. Neurol India. 2003, 51 (3): 323-328.PubMed
19.
Fan J, Varshney RR, Ren L, Cai D, Wang DA: Synovium-derived mesenchymal stem cells: a new cell source for musculoskeletal regeneration. Tissue Eng Part B Rev. 2009, 15 (1): 75-86. 10.1089/ten.teb.2008.0586.PubMedCrossRef
20.
Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simoes BP, et al: Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007, 297 (14): 1568-1576. 10.1001/jama.297.14.1568.PubMedCrossRef
21.
Sangwan VS, Fernandes M, Bansal AK, Vemuganti GK, Rao GN: Early results of penetrating keratoplasty following limbal stem cell transplantation. Indian J Ophthalmol. 2005, 53 (1): 31-35. 10.4103/0301-4738.15282.PubMedCrossRef
22.
Rosa SB, Voltarelli JC, Chies JA, Pranke P: The use of stem cells for the treatment of autoimmune diseases. Braz J Med Biol Res. 2007, 40 (12): 1579-1597.PubMedCrossRef
23.
24.
25.
Nieto Y, Jones RB, Shpall EJ: Stem-cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol. 2004, 26 (1-2): 31-56. 10.1007/s00281-004-0160-8.PubMedCrossRef
26.
Filip S, Mokry J, Horacek J, English D: Stem cells and the phenomena of plasticity and diversity: a limiting property of carcinogenesis. Stem Cells Dev. 2008, 17 (6): 1031-1038. 10.1089/scd.2007.0234.PubMedCrossRef
27.
Vicente-Duenas C, Gutierrez de Diego J, Rodriguez FD, Jimenez R, Cobaleda C: The role of cellular plasticity in cancer development. Curr Med Chem. 2009, 16 (28): 3676-3685. 10.2174/092986709789105019.PubMedCrossRef
28.
Reddy P, Arora M, Guimond M, Mackall CL: GVHD: a continuing barrier to the safety of allogeneic transplantation. Biol Blood Marrow Transplant. 2009, 15 (1 Suppl): 162-168. 10.1016/j.bbmt.2008.10.014.PubMedCrossRef
29.
Zarzeczny A, Caulfield T: Emerging ethical, legal and social issues associated with stem cell research & and the current role of the moral status of the embryo. Stem Cell Rev. 2009, 5 (2): 96-101. 10.1007/s12015-009-9062-4.PubMedCrossRef
30.
Wobus AM, Boheler KR: Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol Rev. 2005, 85 (2): 635-678. 10.1152/physrev.00054.2003.PubMedCrossRef
31.
Oligny LL: Human molecular embryogenesis: an overview. Pediatr Dev Pathol. 2001, 4 (4): 324-343. 10.1007/s10024001-0033-2.PubMedCrossRef
32.
Talbot NC, Powell AM, Rexroad CE: In vitro pluripotency of epiblasts derived from bovine blastocysts. Mol Reprod Dev. 1995, 42 (1): 35-52. 10.1002/mrd.1080420106.PubMedCrossRef
33.
Odorico JS, Kaufman DS, Thomson JA: Multilineage differentiation from human embryonic stem cell lines. Stem Cells. 2001, 19 (3): 193-204. 10.1634/stemcells.19-3-193.PubMedCrossRef
34.
Sjogren A, Hardarson T, Andersson K, Caisander G, Lundquist M, Wikland M, Semb H, Hamberger L: Human blastocysts for the development of embryonic stem cells. Reprod Biomed Online. 2004, 9 (3): 326-329. 10.1016/S1472-6483(10)62149-9.PubMedCrossRef
35.
Cowan CA, Klimanskaya I, McMahon J, Atienza J, Witmyer J, Zucker JP, Wang S, Morton CC, McMahon AP, Powers D, et al: Derivation of embryonic stem-cell lines from human blastocysts. N Engl J Med. 2004, 350 (13): 1353-1356. 10.1056/NEJMsr040330.PubMedCrossRef
36.
Rosler ES, Fisk GJ, Ares X, Irving J, Miura T, Rao MS, Carpenter MK: Long-term culture of human embryonic stem cells in feeder-free conditions. Dev Dyn. 2004, 229 (2): 259-274. 10.1002/dvdy.10430.PubMedCrossRef
37.
Fujioka T, Yasuchika K, Nakamura Y, Nakatsuji N, Suemori H: A simple and efficient cryopreservation method for primate embryonic stem cells. Int J Dev Biol. 2004, 48 (10): 1149-1154. 10.1387/ijdb.041852tf.PubMedCrossRef
38.
Zhou CQ, Mai QY, Li T, Zhuang GL: Cryopreservation of human embryonic stem cells by vitrification. Chin Med J (Engl). 2004, 117 (7): 1050-1055.
39.
Reubinoff BE, Pera MF, Vajta G, Trounson AO: Effective cryopreservation of human embryonic stem cells by the open pulled straw vitrification method. Hum Reprod. 2001, 16 (10): 2187-2194. 10.1093/humrep/16.10.2187.PubMedCrossRef
40.
Hayflick L, Moorhead PS: The serial cultivation of human diploid cell strains. Exp Cell Res. 1961, 25: 585-621. 10.1016/0014-4827(61)90192-6.PubMedCrossRef
41.
Campisi J: From cells to organisms: can we learn about aging from cells in culture?. Exp Gerontol. 2001, 36 (4-6): 607-618. 10.1016/S0531-5565(00)00230-8.PubMedCrossRef
42.
Wright WE, Shay JW: Historical claims and current interpretations of replicative aging. Nat Biotechnol. 2002, 20 (7): 682-688. 10.1038/nbt0702-682.PubMedCrossRef
43.
D'Ippolito G, Schiller PC, Ricordi C, Roos BA, Howard GA: Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res. 1999, 14 (7): 1115-1122.PubMedCrossRef
44.
Brook FA, Gardner RL: The origin and efficient derivation of embryonic stem cells in the mouse. Proc Natl Acad Sci USA. 1997, 94 (11): 5709-5712. 10.1073/pnas.94.11.5709.PubMedCentralPubMedCrossRef
45.
O'Donoghue K, Fisk NM: Fetal stem cells. Best Pract Res Clin Obstet Gynaecol. 2004, 18 (6): 853-875.PubMedCrossRef
46.
Gallacher L, Murdoch B, Wu D, Karanu F, Fellows F, Bhatia M: Identification of novel circulating human embryonic blood stem cells. Blood. 2000, 96 (5): 1740-1747.PubMed
47.
Fortier LA, Nixon AJ, Williams J, Cable CS: Isolation and chondrocytic differentiation of equine bone marrow-derived mesenchymal stem cells. Am J Vet Res. 1998, 59 (9): 1182-1187.PubMed
48.
Deasy BM, Li Y, Huard J: Tissue engineering with muscle-derived stem cells. Curr Opin Biotechnol. 2004, 15 (5): 419-423. 10.1016/j.copbio.2004.08.004.PubMedCrossRef
49.
Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH: Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001, 7 (2): 211-228. 10.1089/107632701300062859.PubMedCrossRef
50.
De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP: Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 2001, 44 (8): 1928-1942. 10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P.PubMedCrossRef
51.
Zarnett R, Salter RB: Periosteal neochondrogenesis for biologically resurfacing joints: its cellular origin. Can J Surg. 1989, 32 (3): 171-174.PubMed
52.
Wong MH: Regulation of intestinal stem cells. J Investig Dermatol Symp Proc. 2004, 9 (3): 224-228. 10.1111/j.1087-0024.2004.09304.x.PubMedCrossRef
53.
Blanpain C, Lowry WE, Geoghegan A, Polak L, Fuchs E: Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. Cell. 2004, 118 (5): 635-648. 10.1016/j.cell.2004.08.012.PubMedCrossRef
54.
Miura M, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG, Shi S: SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci USA. 2003, 100 (10): 5807-5812. 10.1073/pnas.0937635100.PubMedCentralPubMedCrossRef
55.
56.
Young HE, Ceballos EM, Smith JC, Mancini ML, Wright RP, Ragan BL, Bushell I, Lucas PA: Pluripotent mesenchymal stem cells reside within avian connective tissue matrices. In Vitro Cell Dev Biol Anim. 1993, 29A (9): 723-736. 10.1007/BF02631429.PubMedCrossRef
57.
Smart N, Riley PR: The stem cell movement. Circ Res. 2008, 102 (10): 1155-1168. 10.1161/CIRCRESAHA.108.175158.PubMedCrossRef
58.
Behrstock S, Ebert AD, Klein S, Schmitt M, Moore JM, Svendsen CN: Lesion-induced increase in survival and migration of human neural progenitor cells releasing GDNF. Cell Transplant. 2008, 17 (7): 753-762. 10.3727/096368908786516819.PubMedCentralPubMedCrossRef
59.
Wognum AW, Eaves AC, Thomas TE: Identification and isolation of hematopoietic stem cells. Arch Med Res. 2003, 34 (6): 461-475. 10.1016/j.arcmed.2003.09.008.PubMedCrossRef
60.
van Bekkum DW: Bone marrow transplantation. Transplant Proc. 1977, 9 (1): 147-154.PubMed
61.
Mimeault M, Batra SK: Recent progress on tissue-resident adult stem cell biology and their therapeutic implications. Stem Cell Rev. 2008, 4 (1): 27-49. 10.1007/s12015-008-9008-2.PubMedCrossRef
62.
Chen FH, Rousche KT, Tuan RS: Technology Insight: adult stem cells in cartilage regeneration and tissue engineering. Nat Clin Pract Rheumatol. 2006, 2 (7): 373-382. 10.1038/ncprheum0216.PubMedCrossRef
63.
Bianco P, Robey PG, Simmons PJ: Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008, 2 (4): 313-319. 10.1016/j.stem.2008.03.002.PubMedCentralPubMedCrossRef
64.
Menicanin D, Bartold PM, Zannettino AC, Gronthos S: Genomic profiling of mesenchymal stem cells. Stem Cell Rev. 2009, 5 (1): 36-50. 10.1007/s12015-009-9056-2.PubMedCrossRef
65.
Alison MR, Poulsom R, Jeffery R, Dhillon AP, Quaglia A, Jacob J, Novelli M, Prentice G, Williamson J, Wright NA: Hepatocytes from non-hepatic adult stem cells. Nature. 2000, 406 (6793): 257-10.1038/35018642.PubMedCrossRef
66.
Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, Phinney DG: Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA. 2003, 100 (14): 8407-8411. 10.1073/pnas.1432929100.PubMedCentralPubMedCrossRef
67.
Brazelton TR, Rossi FM, Keshet GI, Blau HM: From marrow to brain: expression of neuronal phenotypes in adult mice. Science. 2000, 290 (5497): 1775-1779. 10.1126/science.290.5497.1775.PubMedCrossRef
68.
69.
Tan SC, Pan WX, Ma G, Cai N, Leong KW, Liao K: Viscoelastic behaviour of human mesenchymal stem cells. BMC Cell Biol. 2008, 9: 40-10.1186/1471-2121-9-40.PubMedCentralPubMedCrossRef
70.
Boquest AC, Noer A, Collas P: Epigenetic programming of mesenchymal stem cells from human adipose tissue. Stem Cell Rev. 2006, 2 (4): 319-329. 10.1007/BF02698059.PubMedCrossRef
71.
Mizuno H: Adipose-derived stem cells for tissue repair and regeneration: ten years of research and a literature review. J Nippon Med Sch. 2009, 76 (2): 56-66. 10.1272/jnms.76.56.PubMedCrossRef
72.
Meirelles Lda S, Nardi NB: Methodology, biology and clinical applications of mesenchymal stem cells. Front Biosci. 2009, 14: 4281-4298. 10.2741/3528.CrossRef
73.
Ruhil S, Kumar V, Rathee P: Umbilical cord stem cell: an overview. Curr Pharm Biotechnol. 2009, 10 (3): 327-334. 10.2174/138920109787847529.PubMedCrossRef
74.
Mizoguchi M, Ikeda S, Suga Y, Ogawa H: Expression of cytokeratins and cornified cell envelope-associated proteins in umbilical cord epithelium: a comparative study of the umbilical cord, amniotic epithelia and fetal skin. J Invest Dermatol. 2000, 115 (1): 133-134. 10.1046/j.1523-1747.2000.00031-4.x.PubMedCrossRef
75.
76.
Mizoguchi M, Suga Y, Sanmano B, Ikeda S, Ogawa H: Organotypic culture and surface plantation using umbilical cord epithelial cells: morphogenesis and expression of differentiation markers mimicking cutaneous epidermis. J Dermatol Sci. 2004, 35 (3): 199-206. 10.1016/j.jdermsci.2004.06.003.PubMedCrossRef
77.
Sanmano B, Mizoguchi M, Suga Y, Ikeda S, Ogawa H: Engraftment of umbilical cord epithelial cells in athymic mice: in an attempt to improve reconstructed skin equivalents used as epithelial composite. J Dermatol Sci. 2005, 37 (1): 29-39. 10.1016/j.jdermsci.2004.10.008.PubMedCrossRef
78.
Ruetze M, Gallinat S, Lim IJ, Chow E, Phan TT, Staeb F, Wenck H, Deppert W, Knott A: Common features of umbilical cord epithelial cells and epidermal keratinocytes. J Dermatol Sci. 2008, 50 (3): 227-231. 10.1016/j.jdermsci.2007.12.006.PubMedCrossRef
79.
Mihu CM, Mihu D, Costin N, Rus Ciuca D, Susman S, Ciortea R: Isolation and characterization of stem cells from the placenta and the umbilical cord. Rom J Morphol Embryol. 2008, 49 (4): 441-446.PubMed
80.
In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, Kanhai HH: Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells. 2004, 22 (7): 1338-1345.PubMedCrossRef
81.
Chien JW, Duncan S, Williams KM, Pavletic SZ: Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation - An Increasingly Recognized Manifestation of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2010, 16 (1 Suppl): S106-14. 10.1016/j.bbmt.2009.11.002.PubMedCentralPubMedCrossRef
82.
Moghadam KG, Marghoob B, Alimoghadam K, Shirani S, Ghavamzadeh A: Bronchiolitis obliterans following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2010, 3 (2): 100-101.PubMedCrossRef
83.
Miyagawa-Hayashino A, Sonobe M, Kubo T, Yoshizawa A, Date H, Manabe T: Non-specific interstitial pneumonia as a manifestation of graft-versus-host disease following pediatric allogeneic hematopoietic stem cell transplantation. Pathol Int. 2010, 60 (2): 137-142. 10.1111/j.1440-1827.2009.02492.x.PubMedCrossRef
84.
Bryant DH: Obliterative bronchiolitis in haematopoietic stem cell transplantation: can it be treated?. Eur Respir J. 2005, 25 (3): 402-404. 10.1183/09031936.05.00146604.PubMedCrossRef
85.
Park M, Koh KN, Kim BE, Im HJ, Seo JJ: Clinical features of late onset non-infectious pulmonary complications following pediatric allogeneic hematopoietic stem cell transplantation. Clin Transplant. 2010
86.
Yoshihara S, Yanik G, Cooke KR, Mineishi S: Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007, 13 (7): 749-759. 10.1016/j.bbmt.2007.05.001.PubMedCrossRef
87.
Majeski EI, Paintlia MK, Lopez AD, Harley RA, London SD, London L: Respiratory reovirus 1/L induction of intraluminal fibrosis, a model of bronchiolitis obliterans organizing pneumonia, is dependent on T lymphocytes. Am J Pathol. 2003, 163 (4): 1467-1479.PubMedCentralPubMedCrossRef
88.
Ditschkowski M, Elmaagacli AH, Trenschel R, Peceny R, Koldehoff M, Schulte C, Beelen DW: T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors. Haematologica. 2007, 92 (4): 558-561. 10.3324/haematol.10710.PubMedCrossRef
89.
Kanda Y, Takahashi T, Imai Y, Miyagawa K, Ohishi N, Oka T, Chiba S, Hirai H, Yazaki Y: Bronchiolitis obliterans organizing pneumonia after syngeneic bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant. 1997, 19 (12): 1251-1253. 10.1038/sj.bmt.1700816.PubMedCrossRef
90.
Cordier JF: Bronchiolitis obliterans organizing pneumonia. Semin Respir Crit Care Med. 2000, 21 (2): 135-146. 10.1055/s-2000-9840.PubMedCrossRef
91.
Patriarca F, Skert C, Bonifazi F, Sperotto A, Fili C, Stanzani M, Zaja F, Cerno M, Geromin A, Bandini G, et al: Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation. Haematologica. 2006, 91 (9): 1268-1272.PubMed
92.
93.
Ferrara JL, Deeg HJ: Graft-versus-host disease. N Engl J Med. 1991, 324 (10): 667-674. 10.1056/NEJM199103073241005.PubMedCrossRef
94.
Goker H, Haznedaroglu IC, Chao NJ: Acute graft-vs-host disease: pathobiology and management. Exp Hematol. 2001, 29 (3): 259-277. 10.1016/S0301-472X(00)00677-9.PubMedCrossRef
95.
Nevo S, Enger C, Swan V, Wojno KJ, Fuller AK, Altomonte V, Braine HG, Noga SJ, Vogelsang GB: Acute bleeding after allogeneic bone marrow transplantation: association with graft versus host disease and effect on survival. Transplantation. 1999, 67 (5): 681-689. 10.1097/00007890-199903150-00007.PubMedCrossRef
96.
Fujii N, Takenaka K, Shinagawa K, Ikeda K, Maeda Y, Sunami K, Hiramatsu Y, Matsuo K, Ishimaru F, Niiya K, et al: Hepatic graft-versus-host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001, 27 (9): 1007-1010. 10.1038/sj.bmt.1702997.PubMedCrossRef
97.
Lee JW, Joachim Deeg H: Prevention of chronic GVHD. Best Pract Res Clin Haematol. 2008, 21 (2): 259-270. 10.1016/j.beha.2008.02.010.PubMedCrossRef
98.
99.
Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, Foley R, Socie G, Carter S, Couriel D, et al: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant. 2006, 12 (5): 491-505. 10.1016/j.bbmt.2006.03.004.PubMedCrossRef
100.
Rimkus C: Acute complications of stem cell transplant. Semin Oncol Nurs. 2009, 25 (2): 129-138. 10.1016/j.soncn.2009.03.007.PubMedCrossRef
101.
Tabbara IA, Zimmerman K, Morgan C, Nahleh Z: Allogeneic hematopoietic stem cell transplantation: complications and results. Arch Intern Med. 2002, 162 (14): 1558-1566. 10.1001/archinte.162.14.1558.PubMedCrossRef
102.
Skotnicki AB, Krawczyk J: Veno-occlusive disease--an important complication in hematopoietic cells transplantation. Przegl Lek. 2001, 58 (11): 995-999.PubMed
103.
Lee SH, Yoo KH, Sung KW, Koo HH, Kwon YJ, Kwon MM, Park HJ, Park BK, Kim YY, Park JA, et al: Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Bone Marrow Transplant. 2010, 45 (8): 1287-1293. 10.1038/bmt.2009.349.PubMedCrossRef
104.
Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G, Strugo L, Destro R, Gazzola MV, Varotto S, et al: A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica. 2005, 90 (10): 1396-1404.PubMed
105.
Shah MS, Jeevangi NK, Joshi A, Khattry N: Late-onset hepatic veno-occlusive disease post autologous peripheral stem cell transplantation successfully treated with oral defibrotide. J Cancer Res Ther. 2009, 5 (4): 312-314. 10.4103/0973-1482.59910.PubMedCrossRef
106.
Lakshminarayanan S, Sahdev I, Goyal M, Vlachos A, Atlas M, Lipton JM: Low incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution. Pediatr Transplant. 2010, 14 (5): 618-621. 10.1111/j.1399-3046.2009.01285.x.PubMedCrossRef
107.
Pittenger MF, Martin BJ: Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004, 95 (1): 9-20. 10.1161/01.RES.0000135902.99383.6f.PubMedCrossRef
108.
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002, 99 (10): 3838-3843. 10.1182/blood.V99.10.3838.PubMedCrossRef
109.
Alberio R, Campbell KH, Johnson AD: Reprogramming somatic cells into stem cells. Reproduction. 2006, 132 (5): 709-720. 10.1530/rep.1.01077.PubMedCrossRef
110.
Fairchild PJ, Cartland S, Nolan KF, Waldmann H: Embryonic stem cells and the challenge of transplantation tolerance. Trends Immunol. 2004, 25 (9): 465-470. 10.1016/j.it.2004.07.005.PubMedCrossRef
111.
Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, Paz N, Koren-Michowitz M, Waldman D, Leider-Trejo L, et al: Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009, 6 (2): e1000029-10.1371/journal.pmed.1000029.PubMedCentralPubMedCrossRef
112.
Lindvall O, Kokaia Z: Stem cells for the treatment of neurological disorders. Nature. 2006, 441 (7097): 1094-1096. 10.1038/nature04960.PubMedCrossRef
113.
Lindvall O, Kokaia Z, Martinez-Serrano A: Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat Med. 2004, 10 Suppl: S42-50. 10.1038/nm1064.PubMedCrossRef
114.
Bjorklund LM, Sanchez-Pernaute R, Chung S, Andersson T, Chen IY, McNaught KS, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS, et al: Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA. 2002, 99 (4): 2344-2349. 10.1073/pnas.022438099.PubMedCentralPubMedCrossRef
115.
Arnhold S, Lenartz D, Kruttwig K, Klinz FJ, Kolossov E, Hescheler J, Sturm V, Andressen C, Addicks K: Differentiation of green fluorescent protein-labeled embryonic stem cell-derived neural precursor cells into Thy-1-positive neurons and glia after transplantation into adult rat striatum. J Neurosurg. 2000, 93 (6): 1026-1032. 10.3171/jns.2000.93.6.1026.PubMedCrossRef
116.
Werbowetski-Ogilvie TE, Bosse M, Stewart M, Schnerch A, Ramos-Mejia V, Rouleau A, Wynder T, Smith MJ, Dingwall S, Carter T, et al: Characterization of human embryonic stem cells with features of neoplastic progression. Nat Biotechnol. 2009, 27 (1): 91-97. 10.1038/nbt.1516.PubMedCrossRef
117.
Crooks VA, Snyder J: Regulating medical tourism. Lancet. 2010, 376 (9751): 1465-1466. 10.1016/S0140-6736(10)61993-9.PubMedCrossRef
118.
Barclay E: Stem-cell experts raise concerns about medical tourism. Lancet. 2009, 373 (9667): 883-884. 10.1016/S0140-6736(09)60529-8.PubMedCrossRef
119.
Lau D, Ogbogu U, Taylor B, Stafinski T, Menon D, Caulfield T: Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell. 2008, 3 (6): 591-594. 10.1016/j.stem.2008.11.001.PubMedCrossRef
120.
Pepper MS: Cell-based therapy - navigating troubled waters. S Afr Med J. 2010, 100 (5): 286-288PubMed
121.
Woo P: Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol. 2006, 2 (1): 28-34. 10.1038/ncprheum0084.PubMedCrossRef
122.
123.
Hayward K, Wallace CA: Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2009, 11 (1): 216-10.1186/ar2619.PubMedCentralPubMedCrossRef
124.
Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, Van Laar J, Verburg R, Szer J, Taylor K, Joske D, et al: Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol. 2004, 31 (3): 482-488.PubMed
125.
Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M, Cannell P, Will R, Rule S, Joske D, et al: A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum. 2002, 46 (9): 2301-2309. 10.1002/art.10495.PubMedCrossRef
126.
De Kleer IM, Brinkman DM, Ferster A, Abinun M, Quartier P, Van Der Net J, Ten Cate R, Wedderburn LR, Horneff G, Oppermann J, et al: Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis. 2004, 63 (10): 1318-1326. 10.1136/ard.2003.017798.PubMedCentralPubMedCrossRef
127.
Jallouli M, Frigui M, Hmida MB, Marzouk S, Kaddour N, Bahloul Z: Clinical and immunological manifestations of systemic lupus erythematosus: study on 146 south Tunisian patients. Saudi J Kidney Dis Transpl. 2008, 19 (6): 1001-1008.PubMed
128.
Ioannou Y, Isenberg DA: Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J. 2002, 78 (924): 599-606. 10.1136/pmj.78.924.599.PubMedCentralPubMedCrossRef
129.
Traynor AE, Barr WG, Rosa RM, Rodriguez J, Oyama Y, Baker S, Brush M, Burt RK: Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum. 2002, 46 (11): 2917-2923. 10.1002/art.10594.PubMedCrossRef
130.
Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J, Verda L, Krosnjar N, Quigley K, Yaung K, et al: Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA. 2006, 295 (5): 527-535. 10.1001/jama.295.5.527.PubMedCrossRef
131.
132.
Compston A, Coles A: Multiple sclerosis. Lancet. 2008, 372 (9648): 1502-1517. 10.1016/S0140-6736(08)61620-7.PubMedCrossRef
133.
Katsara M, Matsoukas J, Deraos G, Apostolopoulos V: Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Acta Biochim Biophys Sin (Shanghai). 2008, 40 (7): 636-642. 10.1111/j.1745-7270.2008.00444.x.CrossRef
134.
Ebers GC: Natural history of primary progressive multiple sclerosis. Mult Scler. 2004, 10 (Suppl 1): S8-13. 10.1177/135245850401000103. discussion S13-15PubMedCrossRef
135.
Saccardi R, Mancardi GL, Solari A, Bosi A, Bruzzi P, Di Bartolomeo P, Donelli A, Filippi M, Guerrasio A, Gualandi F, et al: Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood. 2005, 105 (6): 2601-2607. 10.1182/blood-2004-08-3205.PubMedCrossRef
136.
Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E, Carreras E, Graus F, Kashyap A, Openshaw H, et al: Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol. 2002, 249 (8): 1088-1097. 10.1007/s00415-002-0800-7.PubMedCrossRef
137.
Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, Smias C, Eleftheriadis N, Tsimourtou V: Autologous stem cell transplantation in progressive multiple sclerosis--an interim analysis of efficacy. J Clin Immunol. 2000, 20 (1): 24-30. 10.1023/A:1006686426090.PubMedCrossRef
138.
Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR: Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science. 2000, 290 (5497): 1779-1782. 10.1126/science.290.5497.1779.PubMedCrossRef
139.
Lim IG, Schrieber L: Management of systemic sclerosis. Isr Med Assoc J. 2002, 4 (11 Suppl): 953-957.PubMed
140.
Akerkar SM, Bichile LS: Therapeutic options for systemic sclerosis. Indian J Dermatol Venereol Leprol. 2004, 70 (2): 67-75.PubMed
141.
Tyndall A, Black C, Finke J, Winkler J, Mertlesmann R, Peter HH, Gratwohl A: Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet. 1997, 349 (9047): 254-10.1016/S0140-6736(05)64864-7.PubMedCrossRef
142.
van den Hoogen FH, van de Putte LB: Treatment of systemic sclerosis. Curr Opin Rheumatol. 1994, 6 (6): 637-641. 10.1097/00002281-199411000-00015.PubMedCrossRef
143.
Martini A, Maccario R, Ravelli A, Montagna D, De Benedetti F, Bonetti F, Viola S, Zecca M, Perotti C, Locatelli F: Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arthritis Rheum. 1999, 42 (4): 807-811. 10.1002/1529-0131(199904)42:4<807::AID-ANR26>3.0.CO;2-T.PubMedCrossRef
144.
Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C, Finke J, Peter HH, van Laar J, Breedveld FC, et al: Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis. 2001, 60 (6): 577-584. 10.1136/ard.60.6.577.PubMedCentralPubMedCrossRef
145.
Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N, Hachulla E, Philippe P, Sibilia J, Rabian C, et al: Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol. 2002, 119 (3): 726-739. 10.1046/j.1365-2141.2002.03895.x.PubMedCrossRef
146.
McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, Mayes MD, McDonagh KT, Nelson JL, Gooley TA, et al: High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood. 2002, 100 (5): 1602-1610.PubMedCentralPubMed
147.
Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J, Peter HH, Breedveld FC, Fibbe WE, Black C, et al: Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis. 2004, 63 (8): 974-981. 10.1136/ard.2003.011205.PubMedCentralPubMedCrossRef
148.
149.
Cassinotti A, Annaloro C, Ardizzone S, Onida F, Della Volpe A, Clerici M, Usardi P, Greco S, Maconi G, Porro GB, et al: Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut. 2008, 57 (2): 211-217. 10.1136/gut.2007.128694.PubMedCrossRef
150.
Oyama Y, Craig RM, Traynor AE, Quigley K, Statkute L, Halverson A, Brush M, Verda L, Kowalska B, Krosnjar N, et al: Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology. 2005, 128 (3): 552-563. 10.1053/j.gastro.2004.11.051.PubMedCrossRef
151.
Burt RK, Traynor A, Oyama Y, Craig R: High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood. 2003, 101 (5): 2064-2066. 10.1182/blood-2002-07-2122.PubMedCrossRef
152.
Stasi R, Provan D: Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004, 79 (4): 504-522. 10.4065/79.4.504.PubMedCrossRef
153.
Huhn RD, Fogarty PF, Nakamura R, Read EJ, Leitman SF, Rick ME, Kimball J, Greene A, Hansmann K, Gratwohl A, et al: High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood. 2003, 101 (1): 71-77. 10.1182/blood-2001-12-0171.PubMedCrossRef
154.
Urban C, Lackner H, Sovinz P, Benesch M, Schwinger W, Dornbusch HJ, Moser A: Successful unrelated cord blood transplantation in a 7-year-old boy with Evans syndrome refractory to immunosuppression and double autologous stem cell transplantation. Eur J Haematol. 2006, 76 (6): 526-530. 10.1111/j.0902-4441.2006.t01-1-EJH2549.x.PubMedCrossRef
155.
Riechsteiner G, Speich R, Schanz U, Russi EW, Weder W, Boehler A: Haemolytic anaemia after lung transplantation: an immune-mediated phenomenon?. Swiss Med Wkly. 2003, 133 (9-10): 143-147.PubMed
156.
Pratt G, Kinsey SE: Remission of severe, intractable autoimmune haemolytic anaemia following matched unrelated donor transplantation. Bone Marrow Transplant. 2001, 28 (8): 791-793. 10.1038/sj.bmt.1703232.PubMedCrossRef
157.
Sallah S, Wan JY, Hanrahan LR: Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia. Clin Cancer Res. 2001, 7 (4): 791-794.PubMed
158.
Seeliger S, Baumann M, Mohr M, Jurgens H, Frosch M, Vormoor J: Autologous peripheral blood stem cell transplantation and anti-B-cell directed immunotherapy for refractory auto-immune haemolytic anaemia. Eur J Pediatr. 2001, 160 (8): 492-496. 10.1007/s004310100778.PubMedCrossRef
159.
Passweg JR, Rabusin M, Musso M, Beguin Y, Cesaro S, Ehninger G, Espigado I, Iriondo A, Jost L, Koza V, et al: Haematopoetic stem cell transplantation for refractory autoimmune cytopenia. Br J Haematol. 2004, 125 (6): 749-755. 10.1111/j.1365-2141.2004.04978.x.PubMedCrossRef
160.
Eisenbarth GS: Update in type 1 diabetes. J Clin Endocrinol Metab. 2007, 92 (7): 2403-2407. 10.1210/jc.2007-0339.PubMedCrossRef
161.
Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL, Klein R: Diabetic retinopathy. Diabetes Care. 1998, 21 (1): 143-156.PubMedCrossRef
162.
163.
Ingberg CM, Palmer M, Schvarcz E, Aman J: Prevalence of urinary tract symptoms in long-standing type 1 diabetes mellitus. Diabetes Metab. 1998, 24 (4): 351-354.PubMed
164.
Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, Madeira MI, Malmegrim KC, Foss-Freitas MC, Simoes BP, et al: C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009, 301 (15): 1573-1579. 10.1001/jama.2009.470.PubMedCrossRef
165.
Snarski E, Torosian T, Paluszewska M, Urbanowska E, Milczarczyk A, Jedynasty K, Franek E, Jedrzejczak WW: Alleviation of exogenous insulin requirement in type 1 diabetes mellitus after immunoablation and transplantation of autologous hematopoietic stem cells. Pol Arch Med Wewn. 2009, 119 (6): 422-426.PubMed
166.
Trivedi HL, Vanikar AV, Thakker U, Firoze A, Dave SD, Patel CN, Patel JV, Bhargava AB, Shankar V: Human adipose tissue-derived mesenchymal stem cells combined with hematopoietic stem cell transplantation synthesize insulin. Transplant Proc. 2008, 40 (4): 1135-1139. 10.1016/j.transproceed.2008.03.113.PubMedCrossRef
167.
168.
Janson CG, Ramesh TM, During MJ, Leone P, Heywood J: Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis. J Hematother Stem Cell Res. 2001, 10 (6): 913-915. 10.1089/152581601317211015.PubMedCrossRef
169.
Mazzini L, Ferrero I, Luparello V, Rustichelli D, Gunetti M, Mareschi K, Testa L, Stecco A, Tarletti R, Miglioretti M, et al: Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial. Exp Neurol. 2010, 223 (1): 229-37. 10.1016/j.expneurol.2009.08.007.PubMedCrossRef
170.
Mazzini L, Fagioli F, Boccaletti R, Mareschi K, Oliveri G, Olivieri C, Pastore I, Marasso R, Madon E: Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003, 4 (3): 158-161. 10.1080/14660820310014653.PubMedCrossRef
171.
Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, Segura JJ: Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy. 2009, 11 (1): 26-34. 10.1080/14653240802644651.PubMedCrossRef
172.
Papadeas ST, Maragakis NJ: Advances in stem cell research for Amyotrophic Lateral Sclerosis. Curr Opin Biotechnol. 2009, 20 (5): 545-551. 10.1016/j.copbio.2009.09.003.PubMedCrossRef
173.
Astradsson A, Cooper O, Vinuela A, Isacson O: Recent advances in cell-based therapy for Parkinson disease. Neurosurg Focus. 2008, 24 (3-4): E6-10.3171/FOC/2008/24/3-4/E5.PubMedCrossRef
174.
Weintraub D, Comella CL, Horn S: Parkinson's disease--Part 2: Treatment of motor symptoms. Am J Manag Care. 2008, 14 (2 Suppl): S49-58.PubMed
175.
Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, Widner H, Brundin P, Rothwell JC, Odin P, et al: Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain. 1999, 122 (Pt 6): 1121-1132. 10.1093/brain/122.6.1121.PubMedCrossRef
176.
Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, Kupsch A, Crabb L, Odin P, Gustavii B, et al: Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain. 2000, 123 (Pt 7): 1380-1390. 10.1093/brain/123.7.1380.PubMedCrossRef
177.
Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, et al: Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001, 344 (10): 710-719. 10.1056/NEJM200103083441002.PubMedCrossRef
178.
Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, Olanow CW: Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol. 1999, 56 (2): 179-187. 10.1001/archneur.56.2.179.PubMedCrossRef
179.
Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, et al: A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003, 54 (3): 403-414. 10.1002/ana.10720.PubMedCrossRef
180.
Lima C, Pratas-Vital J, Escada P, Hasse-Ferreira A, Capucho C, Peduzzi JD: Olfactory mucosa autografts in human spinal cord injury: a pilot clinical study. J Spinal Cord Med. 2006, 29 (3): 191-203. discussion 204-196PubMedCentralPubMed
181.
Mackay-Sim A, Feron F, Cochrane J, Bassingthwaighte L, Bayliss C, Davies W, Fronek P, Gray C, Kerr G, Licina P, et al: Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3-year clinical trial. Brain. 2008, 131 (Pt 9): 2376-2386. 10.1093/brain/awn173.PubMedCentralPubMedCrossRef
182.
Yoon SH, Shim YS, Park YH, Chung JK, Nam JH, Kim MO, Park HC, Park SR, Min BH, Kim EY, et al: Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: Phase I/II clinical trial. Stem Cells. 2007, 25 (8): 2066-2073. 10.1634/stemcells.2006-0807.PubMedCrossRef
183.
Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM, Nauert GM, Sanberg PR, Kordower JH, Saporta S, et al: Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc Natl Acad Sci USA. 2000, 97 (25): 13877-13882. 10.1073/pnas.97.25.13877.PubMedCentralPubMedCrossRef
184.
Kopyov OV, Jacques S, Lieberman A, Duma CM, Eagle KS: Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp Neurol. 1998, 149 (1): 97-108. 10.1006/exnr.1997.6685.PubMedCrossRef
185.
Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, Burnstein RM, Menon DK, Gillard JH, Pickard J, et al: Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry. 2002, 73 (6): 678-685. 10.1136/jnnp.73.6.678.PubMedCentralPubMedCrossRef
186.
Gaura V, Bachoud-Levi AC, Ribeiro MJ, Nguyen JP, Frouin V, Baudic S, Brugieres P, Mangin JF, Boisse MF, Palfi S, et al: Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain. 2004, 127 (Pt 1): 65-72. 10.1093/brain/awh003.PubMedCrossRef
187.
Palfi S, Nguyen JP, Brugieres P, Le Guerinel C, Hantraye P, Remy P, Rostaing S, Defer GL, Cesaro P, Keravel Y, et al: MRI-stereotactical approach for neural grafting in basal ganglia disorders. Exp Neurol. 1998, 150 (2): 272-281. 10.1006/exnr.1997.6754.PubMedCrossRef
188.
Hauser RA, Sandberg PR, Freeman TB, Stoessl AJ: Bilateral human fetal striatal transplantation in Huntington's disease. Neurology. 2002, 58 (11): 1704-author reply 1704PubMedCrossRef
189.
Rabinovich SS, Seledtsov VI, Banul NV, Poveshchenko OV, Senyukov VV, Astrakov SV, Samarin DM, Taraban VY: Cell therapy of brain stroke. Bull Exp Biol Med. 2005, 139 (1): 126-128. 10.1007/s10517-005-0229-y.PubMedCrossRef
190.
Bang OY, Lee JS, Lee PH, Lee G: Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005, 57 (6): 874-882. 10.1002/ana.20501.PubMedCrossRef
191.
Shyu WC, Lin SZ, Lee CC, Liu DD, Li H: Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial. CMAJ. 2006, 174 (7): 927-933.PubMedCentralPubMedCrossRef
192.
Yiu EM, Kornberg AJ: Duchenne muscular dystrophy. Neurol India. 2008, 56 (3): 236-247. 10.4103/0028-3886.43441.PubMedCrossRef
193.
Torrente Y, Belicchi M, Marchesi C, Dantona G, Cogiamanian F, Pisati F, Gavina M, Giordano R, Tonlorenzi R, Fagiolari G, et al: Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell Transplant. 2007, 16 (6): 563-577.PubMedCrossRef
194.
Neumeyer AM, Cros D, McKenna-Yasek D, Zawadzka A, Hoffman EP, Pegoraro E, Hunter RG, Munsat TL, Brown RH: Pilot study of myoblast transfer in the treatment of Becker muscular dystrophy. Neurology. 1998, 51 (2): 589-592.PubMedCrossRef
195.
Gussoni E, Blau HM, Kunkel LM: The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med. 1997, 3 (9): 970-977. 10.1038/nm0997-970.PubMedCrossRef
196.
Miller RG, Sharma KR, Pavlath GK, Gussoni E, Mynhier M, Lanctot AM, Greco CM, Steinman L, Blau HM: Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study. Muscle Nerve. 1997, 20 (4): 469-478. 10.1002/(SICI)1097-4598(199704)20:4<469::AID-MUS10>3.0.CO;2-U.PubMedCrossRef
197.
Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, Sahenk Z, Benson S, McAndrew PE, Rice R, et al: Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med. 1995, 333 (13): 832-838. 10.1056/NEJM199509283331303.PubMedCrossRef
198.
Tremblay JP, Malouin F, Roy R, Huard J, Bouchard JP, Satoh A, Richards CL: Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant. 1993, 2 (2): 99-112.PubMed
199.
200.
Goldman LE, Eisenberg MJ: Identification and management of patients with failed thrombolysis after acute myocardial infarction. Ann Intern Med. 2000, 132 (7): 556-565.PubMedCrossRef
201.
Menasche P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, et al: The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation. 2008, 117 (9): 1189-1200. 10.1161/CIRCULATIONAHA.107.734103.PubMedCrossRef
202.
Hagege AA, Marolleau JP, Vilquin JT, Alheritiere A, Peyrard S, Duboc D, Abergel E, Messas E, Mousseaux E, Schwartz K, et al: Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients. Circulation. 2006, 114 (1 Suppl): I108-113.PubMed
203.
Siminiak T, Kalawski R, Fiszer D, Jerzykowska O, Rzezniczak J, Rozwadowska N, Kurpisz M: Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: phase I clinical study with 12 months of follow-up. Am Heart J. 2004, 148 (3): 531-537. 10.1016/j.ahj.2004.03.043.PubMedCrossRef
204.
Schachinger V, Assmus B, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Yu J, Corti R, Mathey DG, Hamm CW, et al: Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: insights from the reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial infarction (REPAIR-AMI) trial. Eur J Heart Fail. 2009, 11 (10): 973-979. 10.1093/eurjhf/hfp113.PubMedCrossRef
205.
Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, et al: Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006, 355 (12): 1210-1221. 10.1056/NEJMoa060186.PubMedCrossRef
206.
Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, et al: Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004, 364 (9429): 141-148. 10.1016/S0140-6736(04)16626-9.PubMedCrossRef
207.
Ang LP, Tan DT: Ocular surface stem cells and disease: current concepts and clinical applications. Ann Acad Med Singapore. 2004, 33 (5): 576-580.PubMed
208.
Rama P, Bonini S, Lambiase A, Golisano O, Paterna P, De Luca M, Pellegrini G: Autologous fibrin-cultured limbal stem cells permanently restore the corneal surface of patients with total limbal stem cell deficiency. Transplantation. 2001, 72 (9): 1478-1485. 10.1097/00007890-200111150-00002.PubMedCrossRef
209.
Daya SM, Ilari FA: Living related conjunctival limbal allograft for the treatment of stem cell deficiency. Ophthalmology. 2001, 108 (1): 126-133. 10.1016/S0161-6420(00)00475-9. discussion 133-124PubMedCrossRef
210.
Ilari L, Daya SM: Long-term outcomes of keratolimbal allograft for the treatment of severe ocular surface disorders. Ophthalmology. 2002, 109 (7): 1278-1284. 10.1016/S0161-6420(02)01081-3.PubMedCrossRef
211.
Solomon A, Ellies P, Anderson DF, Touhami A, Grueterich M, Espana EM, Ti SE, Goto E, Feuer WJ, Tseng SC: Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency. Ophthalmology. 2002, 109 (6): 1159-1166. 10.1016/S0161-6420(02)00960-0.PubMedCrossRef
212.
Shimazaki J, Maruyama F, Shimmura S, Fujishima H, Tsubota K: Immunologic rejection of the central graft after limbal allograft transplantation combined with penetrating keratoplasty. Cornea. 2001, 20 (2): 149-152. 10.1097/00003226-200103000-00006.PubMedCrossRef
213.
Mobasheri A, Csaki C, Clutterbuck AL, Rahmanzadeh M, Shakibaei M: Mesenchymal stem cells in connective tissue engineering and regenerative medicine: applications in cartilage repair and osteoarthritis therapy. Histol Histopathol. 2009, 24 (3): 347-366.PubMed
214.
McNair PJ, Simmonds MA, Boocock MG, Larmer PJ: Exercise therapy for the management of osteoarthritis of the hip joint: a systematic review. Arthritis Res Ther. 2009, 11 (3): R98-10.1186/ar2743.PubMedCentralPubMedCrossRef
215.
Srbely JZ: Ultrasound in the management of osteoarthritis: part I: a review of the current literature. J Can Chiropr Assoc. 2008, 52 (1): 30-37.PubMedCentralPubMed
216.
Barron MC, Rubin BR: Managing osteoarthritic knee pain. J Am Osteopath Assoc. 2007, 107 (10 Suppl 6): ES21-27.PubMed
217.
Santaguida PL, Hawker GA, Hudak PL, Glazier R, Mahomed NN, Kreder HJ, Coyte PC, Wright JG: Patient characteristics affecting the prognosis of total hip and knee joint arthroplasty: a systematic review. Can J Surg. 2008, 51 (6): 428-436.PubMedCentralPubMed
218.
Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D: Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician. 2008, 11 (3): 343-353.PubMed
219.
220.
Pai M, Zacharoulis D, Milicevic MN, Helmy S, Jiao LR, Levicar N, Tait P, Scott M, Marley SB, Jestice K, et al: Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol. 2008, 103 (8): 1952-1958. 10.1111/j.1572-0241.2008.01993.x.PubMedCrossRef
221.
Lyra AC, Soares MB, da Silva LF, Fortes MF, Silva AG, Mota AC, Oliveira SA, Braga EL, de Carvalho WA, Genser B, et al: Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease. World J Gastroenterol. 2007, 13 (7): 1067-1073.PubMedCentralPubMedCrossRef
222.
am Esch JS, Knoefel WT, Klein M, Ghodsizad A, Fuerst G, Poll LW, Piechaczek C, Burchardt ER, Feifel N, Stoldt V, et al: Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells. 2005, 23 (4): 463-470. 10.1634/stemcells.2004-0283.PubMedCrossRef
223.
Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, Uchida K, Yamasaki T, Fujii Y, et al: Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006, 24 (10): 2292-2298. 10.1634/stemcells.2005-0542.PubMedCrossRef
224.
Heldwein FL, McCullough TC, Souto CA, Galiano M, Barret E: Localized renal cell carcinoma management: an update. Int Braz J Urol. 2008, 34 (6): 676-689. 10.1590/S1677-55382008000600002. discussion 689-690PubMedCrossRef
225.
Oudard S, George D, Medioni J, Motzer R: Treatment options in renal cell carcinoma: past, present and future. Ann Oncol. 2007, 18 (Suppl 10): x25-31. 10.1093/annonc/mdm411.PubMedCrossRef
226.
Peccatori J, Barkholt L, Demirer T, Sormani MP, Bruzzi P, Ciceri F, Zambelli A, Da Prada GA, Pedrazzoli P, Siena S, et al: Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer. 2005, 104 (10): 2099-2103. 10.1002/cncr.21477.PubMedCrossRef
227.
Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G, Pedrazzoli P, Zambelli A, Bay JO, Francois S, et al: Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol. 2006, 17 (7): 1134-1140. 10.1093/annonc/mdl086.PubMedCrossRef
228.
Artz AS, Van Besien K, Zimmerman T, Gajewski TF, Rini BI, Hu HS, Stadler WM, Vogelzang NJ: Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 2005, 35 (3): 253-260. 10.1038/sj.bmt.1704760.PubMedCrossRef
229.
Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000, 343 (11): 750-758. 10.1056/NEJM200009143431101.PubMedCrossRef
230.
Singletary SE: Breast cancer management: the road to today. Cancer. 2008, 113 (7 Suppl): 1844-1849. 10.1002/cncr.23649.PubMedCrossRef
231.
Biron P, Durand M, Roche H, Delozier T, Battista C, Fargeot P, Spaeth D, Bachelot T, Poiget E, Monnot F, et al: Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant. 2008, 41 (6): 555-562. 10.1038/sj.bmt.1705935.PubMedCrossRef
232.
Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, et al: Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant. 2008, 41 (6): 537-545. 10.1038/sj.bmt.1705940.PubMedCrossRef
233.
Carella AM, Bregni M: Current role of allogeneic stem cell transplantation in breast cancer. Ann Oncol. 2007, 18 (10): 1591-1593. 10.1093/annonc/mdm342.PubMedCrossRef
234.
Gill S, Blackstock AW, Goldberg RM: Colorectal cancer. Mayo Clin Proc. 2007, 82 (1): 114-129. 10.4065/82.1.114.PubMedCrossRef
235.
Benson AB: Epidemiology, disease progression, and economic burden of colorectal cancer. J Manag Care Pharm. 2007, 13 (6 Suppl C): S5-18.PubMed
236.
Nagy VM: Updating the management of rectal cancer. J Gastrointestin Liver Dis. 2008, 17 (1): 69-74.PubMed
237.
Kojima R, Kami M, Hori A, Murashige N, Ohnishi M, Kim SW, Hamaki T, Kishi Y, Tsutsumi Y, Masauzi N, et al: Reduced-intensity allogeneic hematopoietic stem-cell transplantation as an immunotherapy for metastatic colorectal cancer. Transplantation. 2004, 78 (12): 1740-1746. 10.1097/01.TP.0000146194.36297.4E.PubMedCrossRef
238.
Aglietta M, Barkholt L, Schianca FC, Caravelli D, Omazic B, Minotto C, Leone F, Hentschke P, Bertoldero G, Capaldi A, et al: Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. Biol Blood Marrow Transplant. 2009, 15 (3): 326-335. 10.1016/j.bbmt.2008.11.036.PubMedCrossRef
239.
Hashino S, Kobayashi S, Takahata M, Onozawa M, Nakagawa M, Kawamura T, Fujisawa F, Izumiyama K, Kahata K, Kondo T, et al: Graft-versus-tumor effect after reduced-intensity allogeneic hematopoietic stem cell transplantation in a patient with advanced colon cancer. Int J Clin Oncol. 2008, 13 (2): 176-180. 10.1007/s10147-007-0716-4.PubMedCrossRef
240.
Carnevale-Schianca F, Cignetti A, Capaldi A, Vitaggio K, Vallario A, Ricchiardi A, Sperti E, Ferraris R, Gatti M, Grignani G, et al: Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood. 2006, 107 (9): 3795-3803. 10.1182/blood-2005-10-3945.PubMedCrossRef
241.
Schilder RJ, Boente MP, Corn BW, Lanciano RM, Young RC, Ozols RF: The management of early ovarian cancer. Oncology (Williston Park). 1995, 9 (2): 171-182. discussion 185-177
242.
Bay JO, Fleury J, Choufi B, Tournilhac O, Vincent C, Bailly C, Dauplat J, Viens P, Faucher C, Blaise D: Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant. 2002, 30 (2): 95-102. 10.1038/sj.bmt.1703609.PubMedCrossRef
243.
Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ: Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol. 2002, 20 (8): 2017-2024. 10.1200/JCO.2002.08.068.PubMedCrossRef
244.
Papadimitriou C, Dafni U, Anagnostopoulos A, Vlachos G, Voulgaris Z, Rodolakis A, Aravantinos G, Bamias A, Bozas G, Kiosses E, et al: High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial. Bone Marrow Transplant. 2008, 41 (6): 547-554. 10.1038/sj.bmt.1705925.PubMedCrossRef
245.
Sarosy GA, Reed E: Autologous stem-cell transplantation in ovarian cancer: is more better?. Ann Intern Med. 2000, 133 (7): 555-556.PubMedCrossRef
246.
Seidenfeld J, Samson DJ, Bonnell CJ, Ziegler KM, Aronson N: Management of small cell lung cancer. Evid Rep Technol Assess (Full Rep). 2006, 1-154. 143
247.
Souhami RL, Hajichristou HT, Miles DW, Earl HM, Harper PG, Ash CM, Goldstone AH, Spiro SG, Geddes DM, Tobias JS: Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer. Cancer Chemother Pharmacol. 1989, 24 (5): 321-325. 10.1007/BF00304766.PubMedCrossRef
248.
Humblet Y, Symann M, Bosly A, Delaunois L, Francis C, Machiels J, Beauduin M, Doyen C, Weynants P, Longueville J, et al: Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol. 1987, 5 (12): 1864-1873.PubMed
249.
Leyvraz S, Perey L, Rosti G, Lange A, Pampallona S, Peters R, Humblet Y, Bosquee L, Pasini F, Marangolo M: Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol. 1999, 17 (11): 3531-3539.PubMed
250.
Brugger W, Fetscher S, Hasse J, Frommhold H, Pressler K, Mertelsmann R, Engelhardt R, Kanz L: Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. Semin Oncol. 1998, 25 (1 Suppl 2): 42-48.PubMed
251.
Hoelzer D, Gokbuget N, Ottmann O, Pui CH, Relling MV, Appelbaum FR, van Dongen JJ, Szczepanski T: Acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2002, 162-192.
252.
Stone RM, O'Donnell MR, Sekeres MA: Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004, 98-117.
253.
Shah NP: Medical management of CML. Hematology Am Soc Hematol Educ Program. 2007, 371-375.
254.
Quintas-Cardama A, Cortes JE: Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc. 2006, 81 (7): 973-988. 10.4065/81.7.973.PubMedCrossRef
255.
Yee KW, O'Brien SM: Chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc. 2006, 81 (8): 1105-1129. 10.4065/81.8.1105.PubMedCrossRef
256.
Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, Lucas M, Lin T: Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2002, 193-213.
257.
Fagioli F, Zecca M, Locatelli F, Lanino E, Uderzo C, Di Bartolomeo P, Berger M, Favre C, Rondelli R, Pession A, et al: Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission. J Pediatr Hematol Oncol. 2008, 30 (8): 575-583. 10.1097/MPH.0b013e31816e2342.PubMedCrossRef
258.
Frassoni F, Gualandi F, Podesta M, Raiola AM, Ibatici A, Piaggio G, Sessarego M, Sessarego N, Gobbi M, Sacchi N, et al: Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008, 9 (9): 831-839. 10.1016/S1470-2045(08)70180-3.PubMedCrossRef
259.
Ruiz-Arguelles GJ, Gomez-Almaguer D, Morales-Toquero A, Gutierrez-Aguirre CH, Vela-Ojeda J, Garcia-Ruiz-Esparza MA, Manzano C, Karduss A, Sumoza A, de-Souza C, et al: The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant. 2005, 36 (12): 1043-1047. 10.1038/sj.bmt.1705190.PubMedCrossRef
260.
Oehler VG, Radich JP, Storer B, Blume KG, Chauncey T, Clift R, Snyder DS, Forman SJ, Flowers ME, Martin P, et al: Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant. 2005, 11 (2): 85-92. 10.1016/j.bbmt.2004.09.010.PubMedCrossRef
261.
Ohnishi K, Ino A, Kishimoto Y, Usui N, Shimazaki C, Ohtake S, Taguchi H, Yagasaki F, Tomonaga M, Hotta T, et al: Multicenter prospective study of interferon alpha versus allogeneic stem cell transplantation for patients with new diagnoses of chronic myelogenous leukemia. Int J Hematol. 2004, 79 (4): 345-353. 10.1532/IJH97.03160.PubMedCrossRef
262.
Das M, Saikia TK, Advani SH, Parikh PM, Tawde S: Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant. 2003, 32 (2): 125-129. 10.1038/sj.bmt.1704107.PubMedCrossRef
263.
Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A, Maertens J, Slavin S, Majolino I, Nagler A, et al: Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica. 2008, 93 (2): 303-306. 10.3324/haematol.11960.PubMedCrossRef
264.
Tobinai K, Takeyama K, Arima F, Aikawa K, Kobayashi T, Hanada S, Kasai M, Ogura M, Sueoka E, Mukai K, et al: Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004. Cancer Sci. 2007, 98 (9): 1350-1357. 10.1111/j.1349-7006.2007.00556.x.PubMedCrossRef
265.
Isidori A, Motta MR, Tani M, Terragna C, Zinzani P, Curti A, Rizzi S, Taioli S, Giudice V, D'Addio A, et al: Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging. Biol Blood Marrow Transplant. 2007, 13 (10): 1224-1232. 10.1016/j.bbmt.2007.07.004.PubMedCrossRef
266.
Grigg AP, Gibson J, Bardy PG, Reynolds J, Shuttleworth P, Koelmeyer RL, Szer J, Roberts AW, To LB, Kennedy G, et al: A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biol Blood Marrow Transplant. 2007, 13 (5): 560-567. 10.1016/j.bbmt.2006.12.449.PubMedCrossRef
267.
Gutierrez-Aguirre CH, Gomez-Almaguer D, Cantu-Rodriguez OG, Gonzalez-Llano O, Jaime-Perez JC, Herena-Perez S, Manzano CA, Estrada-Gomez R, Gonzalez-Carrillo ML, Ruiz-Arguelles GJ: Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study. Bone Marrow Transplant. 2007, 40 (6): 535-539. 10.1038/sj.bmt.1705769.PubMedCrossRef
268.
Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, et al: Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia. 2003, 17 (5): 841-848. 10.1038/sj.leu.2402905.PubMedCrossRef
269.
Marina Cavazzana-Calvo GC, George Q Daley, De Luca Michele, Ira J Fox, Gerstle Claude, Robert A, Goldstein GH, Katherine A High, Hyun Ok Kim, Hin Peng Lee, Ephrat Levy-Lahad, Lingsong Li BL, Daniel R Marshak, Angela McNab, Munsie Megan, Nakauchi Hiromitsu, Mahendra Rao, Carlos Simon Valles, Srivastava Alok, Sugarman Jeremy, Patrick L Taylor, Veiga Anna, Zoloth Laurie, Wong AL: Guidelines for the Clinical Translation of Stem Cells. Edited by: Research ISfSC. 2008, 19-
270.
Daley GQ: Stem cells: roadmap to the clinic. J Clin Invest. 120 (1): 8-10. 10.1172/JCI41801.
271.
Watt FM, Driskell RR: The therapeutic potential of stem cells. Philos Trans R Soc Lond B Biol Sci. 365 (1537): 155-163.
272.
273.
Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H, Richardson M, Smart NG, Cunningham J, et al: Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol. 2008, 26 (4): 443-452. 10.1038/nbt1393.PubMedCrossRef
274.
Preynat-Seauve O, Burkhard PR, Villard J, Zingg W, Ginovart N, Feki A, Dubois-Dauphin M, Hurst SA, Mauron A, Jaconi M, et al: Pluripotent stem cells as new drugs? The example of Parkinson's disease. Int J Pharm. 2009, 381 (2): 113-121. 10.1016/j.ijpharm.2009.03.003.PubMedCrossRef
275.
Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, et al: Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009, 8 (3): 244-253. 10.1016/S1474-4422(09)70017-1.PubMedCrossRef
276.
Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Alwayn IP, Weimar W, Hoogduijn MJ: Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation. 2009, 87 (6): 896-906. 10.1097/TP.0b013e31819b3d72.PubMedCrossRef
277.
Troeger A, Meisel R, Moritz T, Dilloo D: Immunotherapy in allogeneic hematopoietic stem cell transplantation--not just a case for effector cells. Bone Marrow Transplant. 2005, 35 (Suppl 1): S59-64. 10.1038/sj.bmt.1704849.PubMedCrossRef
278.
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, et al: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008, 371 (9624): 1579-1586. 10.1016/S0140-6736(08)60690-X.PubMedCrossRef
279.
Iyer SS, Co C, Rojas M: Mesenchymal stem cells and inflammatory lung diseases. Panminerva Med. 2009, 51 (1): 5-16.PubMed
280.
Nasef A, Ashammakhi N, Fouillard L: Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms. Regen Med. 2008, 3 (4): 531-546. 10.2217/17460751.3.4.531.PubMedCrossRef
281.
282.
Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, et al: Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009, 4 (5): 381-384. 10.1016/j.stem.2009.04.005.PubMedCrossRef
283.
Yamashita JK: ES and iPS cell research for cardiovascular regeneration. Exp Cell Res. 2010, 316 (16): 2555-2559. 10.1016/j.yexcr.2010.04.004.PubMedCrossRef
284.
Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID, Townes TM, Paterson AJ, et al: Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene. 2005, 24 (9): 1491-1500. 10.1038/sj.onc.1208307.PubMedCentralPubMedCrossRef
285.
Hochedlinger K, Yamada Y, Beard C, Jaenisch R: Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell. 2005, 121 (3): 465-477. 10.1016/j.cell.2005.02.018.PubMedCrossRef
286.
Nair V: Retrovirus-induced oncogenesis and safety of retroviral vectors. Curr Opin Mol Ther. 2008, 10 (5): 431-438.PubMed
287.
Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, et al: Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009, 136 (5): 964-977. 10.1016/j.cell.2009.02.013.PubMedCentralPubMedCrossRef
288.
Maherali N, Hochedlinger K: Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell. 2008, 3 (6): 595-605. 10.1016/j.stem.2008.11.008.PubMedCrossRef
289.
Tenzen T, Zembowicz F, Cowan CA: Genome modification in human embryonic stem cells. J Cell Physiol. 2010, 222 (2): 278-281. 10.1002/jcp.21948.PubMedCrossRef
290.
Zarzeczny A, Scott C, Hyun I, Bennett J, Chandler J, Charge S, Heine H, Isasi R, Kato K, Lovell-Badge R, et al: iPS cells: mapping the policy issues. Cell. 2009, 139 (6): 1032-1037. 10.1016/j.cell.2009.11.039.PubMedCrossRef
291.
Metadata
Title
Stem cells in clinical practice: applications and warnings
Authors
Daniele Lodi
Tommaso Iannitti
Beniamino Palmieri
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2011
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-30-9

Other articles of this Issue 1/2011

Journal of Experimental & Clinical Cancer Research 1/2011 Go to the issue

Review

Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties

Research

Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells

Research

Activation of the hedgehog pathway in chronic myelogeneous leukemia patients

Research

Response to dexamethasone is glucose-sensitive in multiple myeloma cell lines

Research

Leptin promotes melanoma tumor growth in mice related to increasing circulating endothelial progenitor cells numbers and plasma NO production

Research

IsoBED: a tool for automatic calculation of biologically equivalent fractionation schedules in radiotherapy using IMRT with a simultaneous integrated boost (SIB) technique
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits